Abstract
Daily epicutaneous immunotherapy (EPIT) for 12 months with DBV712 250 μg has been shown to be statistically superior to placebo in desensitizing (increasing reactivity threshold) 4-11-year-old peanut-allergic children in a Phase 3 clinical trial (PEPITES). While decreasing the likelihood of accidental ingestion reactions through desensitization is a major goal of food allergy immunotherapy, caregivers and patients also desire a reduction in reaction severity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
